Health

The Unsurpassed Success of Dr. Mark McKenna

Mark McKenna is a doctor specializing in Surgery and Medicine. He is licensed by the Georgia and Florida State Board of Medical Examiners. Dr. Mark McKenna graduated from the Tulane University Medical School. He founded the McKenna Venture Investments. Dr. McKenna also acquired the Universal Mortgage Lending and Uptown Title Incorporation.

The group of companies specialized in design-building, real estate closing services, and finance. The 2005 Hurricane Katrina destroyed New Orleans City and most of his investments. However, he stood firm after the storm and took part in rebuilding New Orleans. He did this by developing low-moderate income housing.

Dr. McKenna moved to Atlanta and started ShapeMed. ShapeMed is a medical facility based on wellness and aesthetic. ShapeMed was later sold to Life Time Fitness Inc. where Dr. McKenna served as the National Medical Director until 2016.

Dr. McKenna is currently the Chief Executive Officer and founder of OVME. OVME is a medical aesthetic company that is formulating elective healthcare using technology. Dr. McKenna is a member of the Entrepreneurs Organization. He used to be a board member of the New Orleans Industrial Development Board and the New Orleans Jazz Festival.

Dr. McKenna’s idea of OVME came from his experience of working in the industry of medical aesthetic. He has worked in the industry for over ten years. The doctor brings his ideas to life through setting goals and practicing visualization. He also mediates at least once a day. For him, a blend of meditation and setting active goals formulate success. Being a leader, he was influenced by other leaders too. He recognizes Michael Bloomberg, Elon Musk, and Barrack Obama as the people who changed his thinking.

Surrounding himself with smart people is a strategy that helps Dr. Makennagrow his business enterprises. Dr. McKenna’s habit of reading makes him more productive as an entrepreneur. He is excited that the smoking pattern is decreasing in America. Dr. McKenna lives a normal life like most people. On a normal day he wakes up at 6:30 am and makes breakfast with his daughter. He is happily married and a father of two.

Read More  Click Here

Dr. Jennifer Walden Helps People Obtain Plastic Surgery

The plastic surgery center along with ambulatory surgery center, Dr. Walden is located in the Austin, Texas region. Along with being a certified plastic surgeon Dr. Walden is a well known media commentator and founder for the Jennifer Walden Cosmetic Center.

Dr. Walden started off her career through the Manhattan Eye, Ear and Throat Surgery Center in Manhattan. She studied under her mentor Dr. Sherrell Aston. She was honored through the Harper Bazaar Best Beauty Surgeons of the year 2014.

Dr. Walden has served as an expert commentator on ABC News, Fox and 90210. Also serving as an active member for Modern Aesthetics and Plastic Surgery Practice. There is a very limited number of women who are plastic and cosmetic surgeons in United States. She also worked hard to be a co-author on the textbook for Aesthetics.

Born in Austin, Texas, Dr. Walden returned to the area after giving birth to twin sons in New York. After her sons were born, Jennifer returned to the Austin area in order to be closer to family and friends. Once she returned to Austin, she quickly worked to open her own practice and go on to be a successful plastic surgeon.

After returning to Texas in 2011, Dr. Walden opened her practice in Westlake Falls and then went on to open a satellite office in the Marble Hills area of Texas in 2014. Jennifer Walden has been committed to providing the best for her family and by showing her children stability, Dr. Walden is doing her very best for her children and patients.

To Know More Click Here

Dr. Walden is one of the very few people who use 3-D technology to allow her patients to see the before and after of their surgery. With the 3-D imaging, patients are able to better understand what they will look like following surgery.

Tony Petrello Protects The Future Generations By Investing In The Health Sector

Whenever the words ‘oil and natural gas’ are mentioned, it is peculiar that the name Tony Petrello wouldn’t miss out. Tony is at the helm of one of the most lucrative multi-billion business venture that is involved in drilling oil and natural gas across the globe. He is the managing director of Nabors Industries, having been a deputy chairman from 2003 to 2012, before being appointed to the post of chairman, president, and managing director after that.

Before joining Nabors, he was working with a law firm known as Baker and McKenzie, and he was involved in dealing with international humanitarian laws, revenue returns, and corporate law. He also has a managerial position at Stewart & Stevenson, which is another law firm. The above ventures along with others such as being the board partner of Texas Children Centre have made Tony a very wealthy guy. For instance, his compensation in 2016 is valued to be $ 15,372,429.

He is a graduate of Yale University, and he graduated with a J.D from the institution. Later, he acquired an M.S in Mathematics from Harvard University. The lengthy period of studies imparted him with extensive knowledge that enables him to maneuver the corporate environment with relative ease. He has continually kept up with technological advancements to measure up with the daily challenges at work. Tony Petrello was born in 1955, and since childhood, he showed signs of being an avid risk taker. Today he is conquering the world because he never feared to try out new things, and he became comfortable in the situations that other people would otherwise give up.

Tony and Cynthia Petrello understand the importance of supporting the community. Challenges have come their way, and they have stood firmly by each other all along. For instance, CarenaPetrello, who is currently eight years old, suffers from periventricular Leukomalacia that has made her end up with cerebral palsy. The condition has affected her life since she was born, and she continues to rely on support from her parents and doctors in order to go through her daily life.

However, thanks to the investment made by her father and the research that is being undertaken by scientists, she is becoming better each step of the way. Tony Petrello offered $6 million to assist scientist in the process of acquiring resources that are needed to ensure that children like CarenaPetrello can be able to live a healthy life as much as the challenges may be monumental.

Read More Click Here

Clay Siegall invents ADCetris, one of the most innovative cancer drugs in decades

For anyone who has watched a loved one go through cancer treatment, one of the most obviously horrific aspects of the process are the terrible side effects that people must endure when taking chemotherapeutic agents. Between the loss of hair, constant nausea and risk of death from the drugs themselves, chemotherapy marks one of the most brutal treatments of any disease currently in existence.

For as long as chemotherapy has existed, researchers have attempted to find ways to reduce the horrible side effects associated with this life-saving drug. One of the ways in which it has long been hypothesized that this may be possible is through the direct targeting of malignant tissues instead of systemically releasing large amounts of poison into the bloodstream. The problem with systemic release of chemotherapy, the form of administering the drug that has been traditionally been used in almost all types of cancer treatment, is that the drugs target all fast-reproducing cell types, including healthy cells that are necessary for the normal function of the body.

But one company, Seattle Genetics, led by CEO Clay Siegall, has developed a class of drugs that have actually been able to realize this dream of researchers. Seattle Genetics’ main drug, ADCetris, is an antibody drug conjugate that is capable of delivering highly lethal cytotoxins directly to the site of malignant tumors, therefore, nearly completely eliminating the side effects associated with traditional chemotherapeutic regimes.

This is a highly novel and unprecedented type of drug. In 2011, Seattle Genetics was given FDA approval for the full use of ADCetris on the open market, thereby enabling the drug to be given to the public at-large for the treatment of refractory non-Hodgkin’s lymphoma. The drug has roundly proven itself, providing one of the first mortality decreases for non-Hodgkin’s lymphoma that the disease has seen in more than 30 years.

The astounding success of this drug has made Dr. Clay Siegall and nearly household name, at least among those interested in the biotech space. Dr. Siegall believes his company will receive FDA approval on up to a dozen new drugs over the next five years.

Oncotarget Spreads Free Information

Oncotarget is a journal that publishes free papers online every week that are available to everyone. They also include an option for users to print these documents. The intent of Oncotarget is to spread the public’s knowledge by making various scientific research results available as soon as they are released. This will allow new discoveries to be shared more quickly and it will also build a bridge between different specialities in order to make the communities more accessible to each other. This also has worked to encourage collaboration in biomedical sciences. Oncotarget is considered to a revolutionary advance in the sharing network inside of the medical field. It is going to lead a great system of information and will greatly increase the access that everyone, including the public and medical professionals, have to the plethora of research that is being gathered every day. Download output styles at Endnote.com.

Since their main goal is to end all disease, Oncotarget decided to focus specifically on combating cancer. They have made huge strides in the organization of all of this information and this has benefited the families of those who are suffering from cancer because they have access to a greater amount of information about the disease. The journal focuses specifically on potential therapy treatments and the current standing of treatment protocols. It focuses on the perspective of the patient and uses that to generate ideas for improved and more innovative management programs. They also worked with therapeutic agencies in order to further that sector. They supply their readers with all the evidence that is backing this research, and they discuss the potential therapies that could come into effect in the future. Oncotarget is thriving under the impressive leadership hands of Mikhail Blagosklonny and Andrei V. Gudkov, the editors in chief of the journal. Oncotarget runs through the intricate Index Medicus abstract. They run a highly efficient system and they are growing in popularity with authors in the medical field. In addition to their focus on oncology, Oncotarget also has in depth information on chromosomes, stems cells, neuroscience, cell diseases, gerotarget, and pathology. They also publish papers about age related disease, immunology, and endocrinology.

Read more: http://www.scimagojr.com/journalsearch.php?q=19900191708&tip=sid

Scott Rocklage: The Science and Biopharmaceutical Genius

Dr. Scott M. Rocklage is a renowned scientist, scholar, and entrepreneur based in Boston. He currently serves as a managing partner of 5 AM Venture Management, a California-based venture capital firm that financed science companies. Scott studied at the University of California, from where he graduated with a BSC in chemistry. He is also Ph.D. holder in Chemistry from the celebrated Massachusetts Institute of Technology. His research project was conducted at a lab named after Richard R. Schrock, a Nobel Prize in Chemistry Winner. Dr. Scott has more than 30 U.S. patents, either invented or co-invented, and over 100 peer-reviewed publications to his name.

 

Experience

 

Dr. Scott Rocklage boasts of over 30 years of experience in healthcare management. He served the executive director of Cubist Pharmaceuticals from 1994 to 2001 and the founding CEO from 1994 to 2003. He held research and development positions at Salutar and Catalytica Pharmaceuticals. Scott served as the president and CEO at Nycomed Salutar from 1990 to 1994. Between 1992 and 1994, he was the CEO, president, and board chairman at Nycomed Interventional. From 2007 to 2014, he was acting as the Director of Relypsa and Novira Therapeutics.

 

Dr. Scott’s strategic leadership skills were instrumental in the approval of three drugs, Omniscan, Cubicin, and Teslascan by The Food and Drugs Administration. He was the director of EPIRUS Biopharmaceuticals, Inc. from 2000 to 2004 and Achaogen Inc. from 2014 to 2016. Dr. Scott also served as the executive chairman of Miikana Therapeutics Inc. and Semprus. In 2016, Dr. Scott served briefly as the acting CEO at EPIRUS Biopharmaceuticals.

 

In 2012, Dr. Scott was appointed as the chairman of Novira Therapeutics, a position he holds to date. Since 2013, he has served as the board chairman at Cidara Therapeutics. Dr. Scott was a board director of Semprus BioSciences Corp. For over ten years now, Scott has served as a director of Pulmatrix, Inc. He joined 5 AM Venture Management in 2003 as a venture partner. A year later, Dr. Scott became a managing partner at the firm, a position he has held up to today. He also serves as a director at MDS Proteomics, a Spanish Biotechnology company.